| abstract |
Emphysema and COPD are diagnosed, and the efficacy of therapeutic drug candidates for the treatment of emphysema and/or COPD is evaluated, by determining biomarkers selected from the group SpB, desmosine, VEGF3 IGFBP2, MMP12, TIMPl, MMP9, Crabp2, Rbpl, Cyp26al, Tgm2, Timρ3, Adaml7, Serpinal, Slpi, Collal, EIn, TGFβl, TGFβ-RII, Sftpal, Csf2, Cxcll, Cxcl2, Cxcl5, IL-8Rβ, IL-8Rα, IL-6, TNF, EGF-R, Areg, PDGFα, HpGF, FGF7, Kdr, fltl, Angptl, Tek, HIFlα, Hyoul, PGF, and tropoelastin. |